Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Receives $1,008.96 Consensus Target Price from Brokerages

Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) have been assigned a consensus rating of “Moderate Buy” from the twenty-two analysts that are currently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, four have given a hold recommendation, sixteen have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $1,027.55.

A number of brokerages have recently commented on REGN. Sanford C. Bernstein began coverage on Regeneron Pharmaceuticals in a research note on Tuesday, March 12th. They issued an “outperform” rating and a $1,125.00 price target for the company. Truist Financial reaffirmed a “buy” rating and set a $1,135.00 target price on shares of Regeneron Pharmaceuticals in a research report on Wednesday, April 3rd. StockNews.com lowered Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, April 30th. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $925.00 target price on shares of Regeneron Pharmaceuticals in a research report on Friday, May 3rd. Finally, Evercore ISI assumed coverage on Regeneron Pharmaceuticals in a research report on Tuesday, May 14th. They set an “outperform” rating and a $1,150.00 target price for the company.

Insider Buying and Selling

In other news, Director Bonnie L. Bassler sold 756 shares of the business’s stock in a transaction that occurred on Monday, June 24th. The stock was sold at an average price of $1,062.00, for a total transaction of $802,872.00. Following the completion of the sale, the director now owns 1,382 shares in the company, valued at $1,467,684. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In other Regeneron Pharmaceuticals news, Director Bonnie L. Bassler sold 756 shares of the firm’s stock in a transaction on Monday, June 24th. The shares were sold at an average price of $1,062.00, for a total value of $802,872.00. Following the transaction, the director now directly owns 1,382 shares of the company’s stock, valued at $1,467,684. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Michael S. Brown sold 1,172 shares of the business’s stock in a transaction dated Tuesday, May 28th. The stock was sold at an average price of $974.86, for a total transaction of $1,142,535.92. Following the sale, the director now directly owns 1,382 shares of the company’s stock, valued at $1,347,256.52. The disclosure for this sale can be found here. In the last three months, insiders have sold 61,971 shares of company stock valued at $61,217,654. 7.48% of the stock is owned by company insiders.

Institutional Trading of Regeneron Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of REGN. West Paces Advisors Inc. boosted its holdings in Regeneron Pharmaceuticals by 575.0% during the first quarter. West Paces Advisors Inc. now owns 27 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 23 shares during the last quarter. Crewe Advisors LLC bought a new stake in Regeneron Pharmaceuticals in the 1st quarter worth about $28,000. Fortitude Family Office LLC bought a new stake in Regeneron Pharmaceuticals in the 4th quarter worth about $31,000. MCF Advisors LLC grew its position in Regeneron Pharmaceuticals by 50.0% in the 4th quarter. MCF Advisors LLC now owns 36 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 12 shares in the last quarter. Finally, Criterion Capital Advisors LLC bought a new stake in Regeneron Pharmaceuticals in the 4th quarter worth about $37,000. 83.31% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Stock Up 0.0 %

Shares of REGN opened at $1,051.03 on Thursday. Regeneron Pharmaceuticals has a 52 week low of $688.52 and a 52 week high of $1,081.17. The stock has a market capitalization of $115.81 billion, a price-to-earnings ratio of 31.05, a PEG ratio of 2.17 and a beta of 0.13. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.51 and a current ratio of 5.27. The stock has a fifty day moving average of $984.27 and a 200-day moving average of $951.01.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported $7.97 EPS for the quarter, missing analysts’ consensus estimates of $8.46 by ($0.49). Regeneron Pharmaceuticals had a net margin of 29.45% and a return on equity of 16.83%. The firm had revenue of $3.15 billion during the quarter, compared to the consensus estimate of $3.19 billion. As a group, sell-side analysts anticipate that Regeneron Pharmaceuticals will post 37.23 earnings per share for the current fiscal year.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.